

PRODUCT INFORMATION




Oritavancin (phosphate)

Item No. 24091

CAS Registry No.: 192564-14-0
Formal Name: (4'R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl- α -L-arabino-hexopyranosyl)-N^{3'}-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-vancomycin, diphosphate

Synonym: LY 333328
MF: C₈₆H₉₇Cl₃N₁₀O₂₆ • 2H₃PO₄
FW: 1,989.1
Purity: ≥98%
UV/Vis.: λ_{max} : 273 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oritavancin (phosphate) is supplied as a crystalline solid. A stock solution may be made by dissolving the oritavancin (phosphate) in the solvent of choice, which should be purged with an inert gas. Oritavancin (phosphate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of oritavancin (phosphate) in these solvents is approximately 0.1 mg/ml.

Description

Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria.¹ It inhibits transglycosylation and transpeptidation in the bacterial cell wall to disrupt membrane integrity.^{2,3} Oritavancin inhibits the growth of clinical isolates from skin and soft-tissue infections, including methicillin-resistant and -susceptible *S. aureus* (MRSA, MSSA), vancomycin-resistant and -susceptible *E. faecium* (VREF, VSRF), as well as other staphylococci, streptococci, and enterococci (MIC_{90s} = ≤0.008-0.5 mg/L).⁴ Oritavancin inhibits growth of *S. aureus* in a neutropenic-mouse thigh model of infection (ED₅₀ = 0.95 mg/kg for a single dose).⁵ It improves survival in a mouse inhalation model of *B. anthracis* Ames anthrax when administered prophylactically pre- and postexposure and when administered post symptom development.⁶ Formulations containing oritavancin have been used to treat bacterial skin infections.

References

1. Jones, R.N., Barrett, M.S., and Erwin, M.E. *Antimicrob. Agents Chemother.* **41(2)**, 488-493, (1997).
2. Zhanel, G.G., Schweizer, F., and Karlowsky, J.A. *Clin. Infect. Dis.* **54(Suppl 3)**, S214-S219 (2012).
3. Belley, A., McKay, G.A., Arhin, F.F., et al. *Antimicrob. Agents Chemother.* **54(12)**, 5369-5371 (2010).
4. Mendes, R.E., Farrell, D.J., Sader, H.S., et al. *J. Antimicrob. Chemother.* **70(2)**, 498-504 (2015).
5. Boylan, C.J., Campanale, K., Iversen, P.W., et al. *Antimicrob. Agents Chemother.* **47(5)**, 1700-1706 (2003).
6. Heine, H.S., Bassett, J., Miller, L., et al. *Antimicrob. Agents Chemother.* **52(9)**, 3350-3357 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM